Medtronic Q3 Revenue Climbs 8.7% as Cardiovascular Sales Surge 13.8%
Medtronic posted fiscal Q3 revenue of $9.0B, up 8.7% as reported and 6.0% organically, with adjusted EPS of $1.36 driven by 13.8% Cardiovascular growth and 137% U.S. increase in Cardiac Ablation Solutions. Shares fell 0.5% and management maintained FY26 guidance for 5.5% organic revenue growth and $5.62–$5.66 EPS.
1. Fiscal Q3 Results
Medtronic posted FY26 Q3 revenue of $9.0B, up 8.7% as reported and 6.0% organically, with adjusted EPS of $1.36, surpassing consensus and marking the highest enterprise revenue growth in 10 quarters.
2. Segment Performance
Cardiovascular sales rose 13.8% as reported and 10.6% organically to $3.46B, driven by an 80% global and 137% U.S. jump in Cardiac Ablation Solutions. Neuroscience climbed 4.1% to $2.56B, Medical Surgical increased 4.9% to $2.17B, and Diabetes grew 14.8% to $796M.
3. Post-Earnings Reaction and Outlook
Shares dipped 0.5% after the release despite the beat. Management reaffirmed FY26 targets of approximately 5.5% organic revenue growth and $5.62–$5.66 adjusted EPS, accounting for a potential $185M tariff headwind.
4. Hemostasis Products Market Forecast
The global hemostasis products market is projected to expand from $1.94B in 2025 to $3.28B by 2035 at a 5.41% CAGR, led by North America’s 41.6% share, while high costs and low reimbursement remain challenges in developing markets.